Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.

ABSTRACT:

Background

High inter-individual variability in therapeutic response to drugs used in the management of Inflammatory Bowel Disease (IBD) leads to high morbidity and high costs. Genetic variants predictive of thiopurine-induced myelosuppression, thiopurine-induced pancreatitis and immunogenicity of Tumour Necrosis Factor alpha (TNFα) antagonists have been identified, but uptake of pre-treatment pharmacogenetic testing into clinical guidelines has been slow.

Aim

To explore the efficacy of a pharmacogenetic passport for IBD that includes multiple pharmacogenetic predictors of response.

Methods

Patients with IBD exposed to thiopurines and/or TNFα antagonists were retrospectively evaluated for the presence of thiopurine toxicity and/or immunogenicity of TNFα antagonists. A

SUBMITTER: Bangma A 

PROVIDER: S-EPMC7318341 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature